Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-969

Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Achondroplasia is a rare genetic disorder caused by mutations in the Fibroblast Growth Factor receptor 3 (FGFR3). These mutations lead to aberrant increase of inhibitory signaling in proliferating chondrocytes at the growth plate. Recifercept is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3). Recifercept is a potential treatment for this disease using a decoy approach to sequester FGFR3 ligands subsequently normalizing activation of the mutated FGFR3 receptor. Recifercept binds to FGF isoforms in vitro and in cellular model systems and reduces FGFR3 signaling.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-969-1mg 1mg 3090
GMP-Bios-INN-969-10mg 10mg Inquiry
GMP-Bios-INN-969-100mg 100mg Inquiry
GMP-Bios-INN-969-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF
INN Name Recifercept
TargetFGF
FormatRecombinant Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFGFR3 (fibroblast growth factor receptor 3, ACH, achondroplasia, thanatophoric dwarfism, CEK2, CD333) Soluble
VD LCFGFR3 (fibroblast growth factor receptor 3, ACH, achondroplasia, thanatophoric dwarfism, CEK2, CD333) Soluble
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesPfizer (New York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0